HDAC6 and rheumatoid arthritis: Moreover, the therapeutic effect of a novel specific HDAC6 inhibitor, CKD-L, compared to the pan HDAC inhibitors, ITF 2357 or Tubastatin A on CIA and Treg cells isolated from RA patients.